
-
Hitchcock heroine Novak awarded Venice lifetime achievement award
-
UK to boost 'homegrown talent' in new AI skills drive
-
Beaten Sinner extends lead on Alcaraz at top of ATP rankings
-
Strycova to replace Pala as Czech Billie Jean King Cup team captain
-
Defence or environment? London faces spending choices
-
'Tennis the winner' as Alcaraz and Sinner set for enduring rivalry
-
Don't let deep sea become 'wild west', Guterres tells world leaders
-
Chivu says goodbye to Parma ahead of Inter Milan move
-
Iran says to submit own nuclear proposal to US soon
-
Boisson jumps 296 places in WTA rankings after French Open run
-
China's exports slow as trade war takes toll
-
Tangled humpback whale sparks rescue mission off Australia
-
Malaysia bus crash kills at least 15, mostly students
-
Climate change heightens risk of Indian farmer suicides
-
Farmed production of some fish - and seaweed - is soaring
-
Bust attributed to Donatello splits Slovakia
-
Israel diverts Gaza-bound aid boat carrying Greta Thunberg
-
China exports slow as trade war takes toll
-
'Maybe Happy Ending' tops Broadway's Tony Awards
-
'Flawed' Test Championship reveals world cricket's underlying problems
-
Retired great Hakuho says leaving sumo after bullying scandal
-
Haliburton vows to improve after Thunder defense stifles Pacers
-
Trump travel ban in effect, citizens from 12 nations barred from US
-
McIntosh impresses in 800m free win at Canada trials
-
NATO learns as Ukraine's 'creativity' changes battlefield
-
Thunder rumble to 123-107 win over Pacers to level NBA Finals
-
Israel says Gaza-bound activist boat carrying Greta Thunberg redirected
-
Chinese consumer prices continue to fall as US trade talks loom
-
Thunder power past Pacers to level NBA Finals
-
Asian markets rally ahead of latest China-US trade talks
-
UN summit to tackle 'emergency' in world's oceans
-
Alexandre de Moraes: Brazilian judge in showdown with far-right
-
US, China seek to extend trade truce with London talks
-
Zedge's DataSeeds.AI Releases Foundational Dataset for Computer Vision and Generative AI in Collaboration with Perle.ai and Émet Research
-
Highlander Silver Commences Drilling at Bonanza Grade San Luis Gold-Silver Project
-
Empire Metals Limited Announces Exceptional High-Purity TiO2 Product Achieved
-
Angle PLC Announces Posting of Annual Report and Notice of AGM
-
Guardian Metal Joins Critical Minerals Forum
-
Fox beats Burns on fourth playoff hole to win PGA Canadian Open
-
Nations League victors Portugal toast Ronaldo's 'winner mentality'
-
Spain focused on World Cup after defeat, says coach
-
New Zealand Rugby chief Robinson quits
-
Lewandowski to boycott national team under current coach
-
Portugal beat Spain on penalties to win Nations League
-
Alcaraz puts French Open miracle down to 'real champions' mindset
-
Kupcho ends LPGA title drought with Shoprite Classic crown
-
Alcaraz stuns Sinner in all-time great French Open final
-
'This one hurts': Sinner wants to forget painful French Open final loss
-
Powerful 6.3 magnitude quake shakes central Colombia, damaging buildings
-
'They could be here in two days': Ukrainian town braces for Russian advance

Angle PLC Announces Posting of Annual Report and Notice of AGM
GUILDFORD, SURREY / ACCESS Newswire / June 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report and Financial Statements for the year ended 31 December 2024, and the Notice of Annual General Meeting ("AGM") within it, have been posted to shareholders, and are available on the Company's website.
The AGM will be held at 2:00 pm on Monday 30 June 2025 at the Surrey Technology Centre, Surrey Research Park, Guildford, Surrey GU2 7YG. The Board is looking forward to welcoming shareholders in person and will provide a business update after the formalities of the meeting are concluded.
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Andrew Newland, Chief Executive Ian Griffiths, Finance Director | |
Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser | +44 (0) 20 3207 7800 |
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) | +44 (0) 203 727 1000 +1 (212) 850 5624 |
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.
Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product:
The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on ACCESS Newswire
O.Norris--AMWN